Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Roche and InterMune have signed an agreement to develop and commercialize candidates from InterMune's hepatitis C protease inhibitor program.
Subscribe to our email newsletter
The agreement includes InterMune's lead compound ITMN-191, which is expected to enter clinical trials before the end of the year. The companies will also collaborate on a research program of novel second-generation hepatitis C protease inhibitors.
“We believe this partnership will help accelerate the development of ITMN-191 and future second-generation protease inhibitors,” said Dan Welch, CEO of InterMune.
Roche will exclusively license ITMN-191 and will have the right to exclusively license further hepatitis C protease inhibitor development candidates resulting from the research collaboration.
InterMune will conduct phase I studies of ITMN-191, and thereafter Roche will lead clinical development and commercialization. Upon closing, InterMune will receive from Roche an upfront payment of $60 million. InterMune could potentially receive up to $470 million in milestones as a result of the deal. The companies will co-commercialize the product in the US.
The economic terms for ITMN-191 could also apply to additional compounds that InterMune and Roche develop.
The transaction will close following the expiration or early termination of an antitrust regulatory waiting period.